Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapy.

Murat Araz Ismail BeypinarFatih InciLokman KoralMehmet Zahid Koçak Mustafa Korkmaz Aykut Demirkıran Melek Karakurt Eryilmaz Mustafa Yıldırım

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)

There was no significant difference between granisetron and palonosetron in both acute and delayed control of emesis in NSCLC patients receiving cisplatin-based HEC.

Keyphrases

chemotherapy induced
liver failure
small cell lung cancer
respiratory failure
advanced non small cell lung cancer
drug induced
aortic dissection
locally advanced
squamous cell carcinoma
radiation therapy
energy transfer
hepatitis b virus
intensive care unit
mechanical ventilation